{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Cancers+-+Small+Intestine&page=2", "query": { "condition": "Gastrointestinal Cancers - Small Intestine", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Cancers+-+Small+Intestine&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T17:25:32.235Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06764771", "title": "A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Tumors" ], "interventions": [ { "name": "BMS-986488", "type": "DRUG" }, { "name": "Adagrasib", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 437, "start_date": "2025-03-25", "completion_date": "2027-10-15", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-06-25T17:25:32.235Z", "location_count": 4, "location_summary": "Hackensack, New Jersey • Allentown, Pennsylvania • Germantown, Tennessee + 1 more", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "Allentown", "state": "Pennsylvania" }, { "city": "Germantown", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06764771" }, { "nct_id": "NCT02890069", "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma" ], "interventions": [ { "name": "PDR001", "type": "BIOLOGICAL" }, { "name": "LCL161", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Panobinostat", "type": "DRUG" }, { "name": "QBM076", "type": "DRUG" }, { "name": "HDM201", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 298, "start_date": "2016-10-14", "completion_date": "2022-02-22", "has_results": false, "last_update_posted_date": "2023-01-11", "last_synced_at": "2026-06-25T17:25:32.235Z", "location_count": 9, "location_summary": "Santa Monica, California • Baltimore, Maryland • Boston, Massachusetts + 6 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02890069" }, { "nct_id": "NCT04585750", "title": "The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Advanced Malignant Neoplasm", "Metastatic Cancer", "Metastatic Solid Tumor", "Lung Cancer", "Ovarian Cancer", "Endometrial Cancer", "Prostate Cancer", "Colorectal Cancer", "Breast Cancer", "Other Cancer", "Locally Advanced", "Head and Neck Cancer", "Gall Bladder Cancer", "Small Cell Lung Cancer", "Small Cell Lung Cancer ( SCLC )", "Small Cell Lung Carcinoma", "NSCLC", "NSCLC (Non-small Cell Lung Cancer)", "SCLC", "Non-Small Cell Lung Carcinoma", "Triple Negative Breast Cancer", "TNBC", "HER2+ Breast Cancer", "Non-Small Cell Lung Cancer", "ER/PR Positive Breast Cancer", "HER2- Breast Cancer", "HER2-positive Breast Cancer", "HER2-negative Breast Cancer", "ER/PR(+), Her2(-) Breast Cancer" ], "interventions": [ { "name": "rezatapopt", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PMV Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 300, "start_date": "2020-10-29", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-06-25T17:25:32.235Z", "location_count": 32, "location_summary": "Irvine, California • La Jolla, California • Los Angeles, California + 25 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04585750" }, { "nct_id": "NCT06270082", "title": "Study of IK-595 in RAS- or RAF-altered Advanced Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Colorectal Cancer", "Pancreatic Cancer", "Malignant Melanoma", "Ras (Kras or Nras) Gene Mutation", "BRAF Gene Mutation", "CRAF Gene Mutation", "Non-Small Cell Lung Carcinoma", "Thyroid Carcinoma", "Gliomas, Malignant" ], "interventions": [ { "name": "IK-595", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ikena Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2023-12-18", "completion_date": "2025-09-08", "has_results": false, "last_update_posted_date": "2025-09-19", "last_synced_at": "2026-06-25T17:25:32.235Z", "location_count": 15, "location_summary": "Duarte, California • Orange, California • Denver, Colorado + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06270082" }, { "nct_id": "NCT02365662", "title": "A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Non-small Cell Lung Cancer", "Triple Negative Breast Cancer", "Colorectal Carcinoma", "Glioblastoma Multiforme" ], "interventions": [ { "name": "ABBV-221", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 46, "start_date": "2015-01-09", "completion_date": "2018-03-15", "has_results": false, "last_update_posted_date": "2018-03-30", "last_synced_at": "2026-06-25T17:25:32.235Z", "location_count": 3, "location_summary": "Boston, Massachusetts • San Antonio, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02365662" }, { "nct_id": "NCT01451632", "title": "A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Squamous Cell Head and Neck Cancer", "Non-small Cell Lung Cancer", "Triple Negative Breast Cancer", "Other Tumors With EGFR Dependence" ], "interventions": [ { "name": "MM-121", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2011-10", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2016-09-08", "last_synced_at": "2026-06-25T17:25:32.235Z", "location_count": 4, "location_summary": "San Francisco, California • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01451632" }, { "nct_id": "NCT00905086", "title": "Psychosocial Adjustment After Radiation Therapy in Patients With Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Cognitive/Functional Effects", "Colorectal Cancer", "Lung Cancer", "Prostate Cancer", "Psychosocial Effects of Cancer and Its Treatment" ], "interventions": [ { "name": "questionnaire administration", "type": "OTHER" }, { "name": "cognitive assessment", "type": "PROCEDURE" }, { "name": "psychosocial assessment and care", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2008-08", "completion_date": "2009-05", "has_results": false, "last_update_posted_date": "2015-09-30", "last_synced_at": "2026-06-25T17:25:32.235Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00905086" }, { "nct_id": "NCT06835569", "title": "A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "PDAC - Pancreatic Ductal Adenocarcinoma", "NSCLC (Non-small Cell Lung Cancer)", "CRC (Colorectal Cancer)", "Advanced Solid Tumors" ], "interventions": [ { "name": "ALTA3263", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed + Cisplatin /Carboplatin", "type": "DRUG" }, { "name": "mFOLFIRINOX", "type": "DRUG" }, { "name": "GnP", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alterome Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 448, "start_date": "2025-03-05", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-06-25T17:25:32.235Z", "location_count": 12, "location_summary": "Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 6 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06835569" }, { "nct_id": "NCT00937482", "title": "Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Male Breast Cancer", "Stage IV Breast Cancer", "Stage IV Melanoma", "Stage IV Non-small Cell Lung Cancer", "Stage IV Renal Cell Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer", "Tumors Metastatic to Brain" ], "interventions": [ { "name": "cediranib maleate", "type": "DRUG" }, { "name": "whole-brain radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2009-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-03-08", "last_synced_at": "2026-06-25T17:25:32.235Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00937482" }, { "nct_id": "NCT01390818", "title": "Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Solid Tumor", "Metastatic Solid Tumor", "Breast Cancer", "Non Small Cell Lung Cancer", "Melanoma", "Colorectal Cancer" ], "interventions": [ { "name": "MSC1936369B (pimasertib)", "type": "DRUG" }, { "name": "SAR245409 (PI3K and mTOR inhibitor)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "82 Years", "sex": "ALL", "summary": "18 Years to 82 Years" }, "enrollment_count": 146, "start_date": "2011-05", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2017-03-07", "last_synced_at": "2026-06-25T17:25:32.235Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Boston, Massachusetts + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01390818" } ] }